Scholarlink

Background <p>The growing incidence and high mortality of malignant tumors render them a persistent challenge to global health. Interleukin enhancer-binding factor 2 (ILF2), a nuclear protein involved in gene regulation, has been found to be aberrantly expressed in various cancers; however, its pan-cancer roles remain unclear.</p> Methods <p>This study presents an extensive pan-cancer analysis We systematically evaluated the expression patterns, prognostic and diagnostic significance, genetic alterations, alternative splicing events, functional pathways, immune infiltration characteristics, and therapeutic responses of ILF2 across diverse cancer types.</p> Results <p>ILF2 was broadly upregulated across multiple cancers and correlated with poor prognosis, genomic alterations, and proliferation-related pathways. Its expression was also associated with immune infiltration and immune subtypes. In hepatocellular carcinoma, ILF2 mainly expresses in malignant hepatocytes at the single-cell RNA-seq level, and high ILF2 predicted therapeutic resistance and worse survival outcomes.</p> Conclusion <p>ILF2 may serve as a potential biomarker for cancer diagnosis, prognosis, and therapeutic targeting. In particular, it holds promise as a novel therapeutic target in hepatocellular carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-omics analysis of ILF2 reveals its prognostic value and functional roles across pan-cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Huan Xiong,
  • Zewei Chen,
  • Junjie Xu,
  • Hailin Tang,
  • Xiaoyan Li,
  • Anli Yang

摘要

Background

The growing incidence and high mortality of malignant tumors render them a persistent challenge to global health. Interleukin enhancer-binding factor 2 (ILF2), a nuclear protein involved in gene regulation, has been found to be aberrantly expressed in various cancers; however, its pan-cancer roles remain unclear.

Methods

This study presents an extensive pan-cancer analysis We systematically evaluated the expression patterns, prognostic and diagnostic significance, genetic alterations, alternative splicing events, functional pathways, immune infiltration characteristics, and therapeutic responses of ILF2 across diverse cancer types.

Results

ILF2 was broadly upregulated across multiple cancers and correlated with poor prognosis, genomic alterations, and proliferation-related pathways. Its expression was also associated with immune infiltration and immune subtypes. In hepatocellular carcinoma, ILF2 mainly expresses in malignant hepatocytes at the single-cell RNA-seq level, and high ILF2 predicted therapeutic resistance and worse survival outcomes.

Conclusion

ILF2 may serve as a potential biomarker for cancer diagnosis, prognosis, and therapeutic targeting. In particular, it holds promise as a novel therapeutic target in hepatocellular carcinoma.